Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101651 | 0.82 | POLB (0.44) | POLBALOX15 | |
| SCHEMBL4097722 | 0.74 | TP53 (0.43) | ALDH1A1HPGDTP53HSD17B10TSHR | |
| SCHEMBL13940793 | 0.67 | FBP1 (0.40) | HPGDKMT2A | |
| SCHEMBL13940792 | 0.67 | PIM1 (0.49) | HPGDTP53KMT2ALMNAKDM4E | |
| Hydrochloric Acid SCHEMBL4102505 | 0.67 | FBP1 (0.39) | HPGD | |
| Hydrochloric Acid SCHEMBL4095397 | 0.67 | PIM1 (0.49) | HPGDTP53KMT2ALMNAKDM4E | |
| SCHEMBL13940794 | 0.66 | DHODH (0.43) | ALDH1A1HPGDPOLBTP53TSHR | |
| Hydrochloric Acid SCHEMBL4095382 | 0.65 | DHODH (0.43) | ALDH1A1HPGDPOLBTP53TSHR | |
| SCHEMBL10299923 | 0.63 | HDAC3 (0.54) | ALDH1A1SMN1; SMN2RAB9ANPC1TSHR | |
| SCHEMBL8092305 | 0.61 | HDAC3 (0.55) | ALDH1A1SMN1; SMN2POLBTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1979358-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018128-A1 | Compounds | CNR2, CNR1, TRPV1 | ALDH1A1 3762/4885HPGD 486/4885SMN1; SMN2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.